Rockwell Medical Reports 11% Revenue Growth to $17.8 Million in Q2 2026

Rockwell Medical, Inc. reported its financial results for the second quarter of 2026, revealing a net sales increase to $17.8 million, up 11% from $16.1 million in the same period last year. For the first half of 2026, net sales reached $35.1 million, a slight increase from $35.0 million in the first half of 2025. The growth in sales was attributed to new customer acquisitions in the Western United States and price increases for existing customers, although sales to DaVita, a significant customer, decreased notably.

The company's gross profit for the second quarter was $3.2 million, compared to $2.5 million in the prior year, reflecting a 30% increase. This improvement was driven by lower manufacturing costs due to a reduction in production headcount and overhead, as well as higher sales volumes. However, the cost of sales also increased to $14.5 million from $13.6 million year-over-year. For the first half of 2026, gross profit was $6.1 million, up from $5.5 million in the same period of 2025, indicating an overall improvement in profitability.

Operationally, Rockwell Medical continues to serve approximately 300 customers, including major dialysis providers in the U.S. The company has focused on expanding its market share within the hemodialysis concentrates sector and has implemented cost containment measures. As of June 30, 2026, Rockwell had approximately $24.8 million in cash, cash equivalents, and investments available-for-sale, with a working capital of $25.2 million. The company reported net cash provided by operating activities of $1.9 million for the first half of 2026, a significant turnaround from the $1.6 million used in the same period of 2025.

In terms of strategic developments, Rockwell Medical entered into an Amended and Restated Products Purchase Agreement with DaVita, which has been extended through December 31, 2026. This agreement includes price increases for products sold. Additionally, the company executed a one-for-ten reverse stock split on July 1, 2026, to comply with Nasdaq's minimum bid price requirement. The reverse stock split was aimed at enhancing the company's stock price and ensuring continued compliance with listing requirements.

Looking ahead, Rockwell Medical's management believes it has sufficient funds to meet operational requirements for at least the next twelve months. However, the company may seek additional capital through its at-the-market facility or other financing methods to support its growth strategy. The management remains cautious about the global economic environment, which could impact future operations, and is focused on executing its business strategy to achieve sustained profitability.